Of these amounts, Auryxia net product revenues were $44,400,000 and $53,200,000 in the fourth quarters of twenty twenty four and 2023 respectively and $152,200,000 and $170,300,000 in 2024 and 2023 respectively. These decreases were primarily driven by a reduction in volume, partially offset by price increases and execution of our contracting strategy to third party payers. As a reminder, in late March twenty twenty five, Auryxia will lose IPX for Licensed collaboration and other revenues was $2,100,000 and $3,000,000 in the fourth quarters of twenty twenty four and 2023 respectively and $8,000,000 in 2024 compared to $24,300,000 in 2023, which included a one time $10,000,000 license agreement related upfront payment. Cost of goods sold was $20,400,000 and $18,700,000 in the fourth quarters of twenty twenty four and 2023, respectively, and $63,200,000 and $74,100,000 in 2024 and 2023 respectively. In the full year 2024 and during the fourth quarter of twenty twenty three, we realized a $12,300,000 benefit and $4,300,000 benefit respectively due to our ability to sell inventory previously written down as excess inventory.